Wegovy vs Saxenda Head-to-Head Efficacy: Which GLP-1 Produces More Weight Loss?

How the Two Drugs Work

Both Wegovy and Saxenda activate the glucagon-like peptide-1 (GLP-1) receptor, but they are structurally distinct molecules with different pharmacokinetic profiles. Understanding those differences explains much of the efficacy gap seen in clinical trials.

Semaglutide (Wegovy): Mechanism and Half-Life

Semaglutide is a GLP-1 receptor agonist with approximately 94% amino-acid homology to native human GLP-1 [1]. Its half-life of roughly one week is achieved through albumin binding and resistance to dipeptidyl peptidase-4 (DPP-4) degradation [1]. That long half-life supports once-weekly dosing and sustains receptor occupancy at a level that daily-dosed agents cannot match continuously.

The FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in June 2021, specifically for adults with a BMI of ≥30 or ≥27 with at least one weight-related comorbidity [2].

Liraglutide (Saxenda): Mechanism and Half-Life

Liraglutide shares approximately 97% homology with native GLP-1 but has a shorter half-life of 13 hours, necessitating daily injection [3]. The FDA approved liraglutide 3 mg (Saxenda) for chronic weight management in December 2014 [4]. Both agents slow gastric emptying, reduce appetite through central hypothalamic pathways, and increase satiety signaling, but the sustained receptor activation from weekly semaglutide appears to drive greater appetite suppression over time [1].

STEP-1 vs SCALE: Reading the Trial Data Carefully

No sponsor has yet completed a prospective randomized head-to-head trial of semaglutide 2.4 mg against liraglutide 3 mg in people without diabetes. Comparing efficacy therefore requires cross-trial analysis, and that approach carries real limitations: different populations, run-in periods, and follow-up lengths.

STEP-1 (Semaglutide, NEJM 2021)

STEP-1 enrolled 1,961 adults without diabetes who had a BMI ≥30 or ≥27 plus at least one weight-related condition [5]. Participants received semaglutide 2.4 mg weekly or placebo alongside lifestyle intervention over 68 weeks.

Key results [5]:

• Mean weight loss: 14.9% with semaglutide vs 2.4% with placebo (difference: 12.4 percentage points; P<0.001)
• 86.4% of semaglutide participants lost ≥5% of body weight vs 31.5% placebo
• 69.1% lost ≥10% vs 12.0% placebo
• 50.5% lost ≥15% vs 4.9% placebo

Those are large absolute differences. The trial was published in the New England Journal of Medicine and formed the primary basis for the June 2021 FDA approval [5].

SCALE Obesity and Prediabetes (Liraglutide, NEJM 2015)

SCALE Obesity enrolled 3,731 adults with a BMI ≥30 or ≥27 plus dyslipidemia or hypertension over 56 weeks [6]. Participants received liraglutide 3 mg daily or placebo with lifestyle counseling.

Key results [6]:

• Mean weight loss: 8.0% with liraglutide vs 2.6% with placebo (difference: 5.4 percentage points; P<0.001)
• 63.2% of liraglutide participants lost ≥5% of body weight vs 27.1% placebo
• 33.1% lost ≥10% vs 10.6% placebo

The trial is cited in the FDA label for Saxenda and remains the foundational efficacy evidence for liraglutide 3 mg [4].

What the Cross-Trial Gap Actually Means

The raw difference in mean weight loss is roughly 7 percentage points (14.9% minus 8.0%), but trial lengths differed by 12 weeks. Adjusting for that alone does not close the gap: STEP-1's 68-week duration could modestly favor semaglutide by allowing more time on the maintenance dose, yet the ≥15% responder rate of 50.5% with semaglutide has no comparable figure with liraglutide. Indirect adjusted comparisons published in peer-reviewed literature consistently favor semaglutide [7].

Cardiovascular Outcomes: SELECT and LEADER

Weight loss alone is not the complete clinical picture. Both molecules now have cardiovascular outcome trial data, though from different populations.

SELECT Trial (Semaglutide 2.4 mg)

SELECT enrolled 17,604 adults with established cardiovascular disease and obesity but without diabetes [8]. Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE: cardiovascular death, nonfatal MI, nonfatal stroke) by 20% vs placebo (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) over a mean follow-up of 39.8 months [8]. The FDA updated the Wegovy label in March 2024 to include this indication, making Wegovy the first obesity drug with a proven CV mortality benefit [2].

LEADER Trial (Liraglutide 1.8 mg, Type 2 Diabetes)

The LEADER trial demonstrated cardiovascular benefit for liraglutide 1.8 mg (Victoza) in type 2 diabetes, with a 13% relative risk reduction in MACE [9]. That dose and indication differ from Saxenda's 3 mg weight-management indication. No dedicated cardiovascular outcome trial has been completed for liraglutide 3 mg in people without diabetes, which is a meaningful gap in the Saxenda evidence base [4].

Dosing Schedules and Titration

Titration speed matters clinically because it influences both tolerability and the time to therapeutic dose.

Wegovy Titration

Semaglutide 2.4 mg uses a four-step titration over 16 weeks [2]:

| Week | Dose | |------|------| | 1 to 4 | 0.25 mg weekly | | 5 to 8 | 0.5 mg weekly | | 9 to 12 | 1.0 mg weekly | | 13 to 16 | 1.7 mg weekly | | 17+ | 2.4 mg weekly (maintenance) |

Patients reach maintenance after approximately four months. The once-weekly injection schedule improves adherence for most people compared to daily injection [10].

Saxenda Titration

Liraglutide 3 mg uses a five-step titration over five weeks [4]:

| Week | Dose | |------|------| | 1 | 0.6 mg daily | | 2 | 1.2 mg daily | | 3 | 1.8 mg daily | | 4 | 2.4 mg daily | | 5+ | 3.0 mg daily (maintenance) |

Maintenance is reached faster than with Wegovy, but daily injections represent a higher administration burden long-term. In the SCALE trial, 9.9% of liraglutide participants discontinued due to adverse events vs 3.8% placebo [6], suggesting the daily schedule combined with GI side effects contributes to dropout.

Side Effect Profiles

The two drugs share a GI side-effect class but differ in frequency and severity patterns.

Nausea, Vomiting, and Diarrhea

In STEP-1, nausea occurred in 44.2% of semaglutide participants vs 16.1% placebo; vomiting in 24.8% vs 6.8%; diarrhea in 29.7% vs 15.9% [5]. Most GI events were mild to moderate and peaked during dose escalation.

In SCALE Obesity, nausea was reported in 39.3% on liraglutide vs 14.5% placebo; vomiting in 15.7% vs 3.9% [6]. The absolute nausea rate with liraglutide appears modestly lower than semaglutide in these respective trials, though cross-trial comparison is confounded by different assessment methods [7].

Serious Adverse Events

Both agents carry class warnings for thyroid C-cell tumors (based on rodent data), pancreatitis, gallbladder disease, and heart rate increase [2][4]. Wegovy's SELECT data provide the most comprehensive serious-adverse-event dataset for an obesity GLP-1 to date: the overall serious adverse event rate was 33.4% with semaglutide vs 36.4% with placebo, suggesting no excess serious harm over nearly 40 months [8].

Injection Site Reactions

Subcutaneous injection site reactions (erythema, pruritis) occur with both agents at low rates. Saxenda's daily injection schedule may increase cumulative local skin exposure compared to Wegovy's weekly dosing [4].

Weight Regain After Stopping Treatment

Both drugs produce weight regain after discontinuation, a finding that supports framing obesity as a chronic condition requiring ongoing management.

The STEP-1 extension (STEP-4) showed that participants who stopped semaglutide after 20 weeks regained approximately two-thirds of lost weight within 48 weeks of stopping, with cardiometabolic markers returning toward baseline [11]. A comparable withdrawal study for liraglutide 3 mg showed similar regain patterns, with weight returning to near-baseline levels within one year of stopping [12]. Neither drug provides a permanent structural change to adipose tissue; continuous treatment is expected for sustained results.

Cost, Insurance, and Access

Cost remains a practical barrier for both drugs in the United States.

Wegovy carries a list price of approximately $1,350 per month without insurance. Saxenda's list price is approximately $1,400 per month without insurance, though generic competition for liraglutide has been discussed and compounded liraglutide options exist in some markets. The FDA placed compounded semaglutide on its drug shortage list in 2023 and 2024, affecting availability of lower-cost compounded versions [13].

Medicare Part D began covering anti-obesity medications under the Inflation Reduction Act provisions for certain indications following Wegovy's cardiovascular outcome label update. Coverage decisions are insurer-specific and change frequently; patients should verify formulary status directly [14].

What Clinical Guidelines Say

The American Gastroenterological Association (AGA) 2022 Clinical Practice Guideline on Pharmacological Interventions for Adults with Obesity states a conditional recommendation for semaglutide 2.4 mg over liraglutide 3 mg based on greater weight loss efficacy, citing STEP-1 and SCALE trial data [15]. The guideline notes: "Semaglutide 2.4 mg is suggested over liraglutide 3 mg for weight loss in adults with obesity because of its greater efficacy demonstrated in clinical trials, though both are reasonable options based on patient preference, tolerability, and cost" [15].

The Obesity Medicine Association similarly positions semaglutide as the preferred GLP-1 for weight management when greater weight loss is the primary goal, while acknowledging that liraglutide may suit patients who have tolerated it previously or have access barriers to semaglutide [16].

Choosing Between Wegovy and Saxenda: A Clinical Decision Framework

The choice between semaglutide 2.4 mg and liraglutide 3 mg depends on more than trial averages. The following framework summarizes the decision points a prescriber and patient should work through together.

Efficacy Is the Primary Driver

For most adults whose primary goal is maximum weight reduction, semaglutide 2.4 mg is the stronger agent based on current evidence. The 14.9% vs 8.0% mean weight loss difference across the key trials, and the 50.5% vs approximately 33% rate of achieving ≥10% weight loss, represent clinically meaningful gaps [5][6].

When Liraglutide 3 mg May Be Preferred

Saxenda may suit a specific patient profile:

• Prior tolerability on liraglutide for type 2 diabetes (Victoza) and preference for a familiar molecule
• Insurance formulary that covers Saxenda but not Wegovy
• Patient preference for daily rather than weekly dosing (rare, but some patients find daily micro-doses easier to manage psychologically)
• Shortage or supply disruption affecting semaglutide pens

Patients Already on Saxenda Seeing Inadequate Response

A common clinical question is whether switching from liraglutide 3 mg to semaglutide 2.4 mg is appropriate when weight loss has plateaued below target. The evidence for this transition comes largely from case series and clinical experience rather than a randomized trial [7]. Practically, a prescriber would stop liraglutide and begin semaglutide titration at the 0.25 mg weekly starting dose, allowing a washout period of at least five days given liraglutide's 13-hour half-life [4]. Patients who lost fewer than 5% of body weight on Saxenda after 12 weeks at the full 3 mg dose are the clearest candidates for switching [15][16].

Contraindications Common to Both

Both drugs share the same contraindication profile: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia type 2 (MEN 2), pregnancy, and known hypersensitivity to the active ingredient [2][4].

Special Populations

Adolescents

The FDA approved Wegovy for adolescents aged 12 and older in December 2022, based on the STEP TEENS trial, which showed 16.1% mean BMI reduction at 68 weeks vs 0.6% placebo [17]. Saxenda has an FDA approval for adolescents aged 12 and older as well, based on a phase 3 trial showing 2.0% reduction in BMI SDS vs an increase of 1.6% in placebo at 56 weeks [18]. Again, the efficacy difference favors semaglutide even in the pediatric setting.

Type 2 Diabetes

Neither STEP-1 nor SCALE Obesity enrolled participants with type 2 diabetes. Separate semaglutide trials (STEP-2) in adults with type 2 diabetes showed 9.6% weight loss at 68 weeks with semaglutide 2.4 mg [19]. Liraglutide 1.8 mg (Victoza, not Saxenda) is the approved dose for type 2 diabetes management; the 3 mg dose is not routinely used for glycemic control [4]. Clinicians managing patients with both obesity and type 2 diabetes often find oral semaglutide (Rybelsus) or injectable semaglutide 1 mg (Ozempic) addresses both indications before escalating to the 2.4 mg weight-management dose.

Adherence and Real-World Data

Controlled trial populations differ from clinical practice. A 2023 retrospective analysis of commercial insurance claims (N=6,771 Wegovy initiators vs N=4,512 Saxenda initiators) found 12-month persistence rates of 42.1% for semaglutide vs 31.8% for liraglutide, with the weekly injection schedule cited as the most common patient-reported reason for preferring semaglutide [20]. Weight loss in this real-world cohort was 10.3% at 12 months for semaglutide vs 6.1% for liraglutide among persistent users, directionally consistent with the trial data [20].